SMP200800011B - Forme cristalline di 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilammino)-benzammide - Google Patents

Forme cristalline di 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilammino)-benzammide

Info

Publication number
SMP200800011B
SMP200800011B SM200800011T SM200800011T SMP200800011B SM P200800011 B SMP200800011 B SM P200800011B SM 200800011 T SM200800011 T SM 200800011T SM 200800011 T SM200800011 T SM 200800011T SM P200800011 B SMP200800011 B SM P200800011B
Authority
SM
San Marino
Prior art keywords
methyl
ylamino
benzamide
imidazol
pyrimidin
Prior art date
Application number
SM200800011T
Other languages
English (en)
Italian (it)
Other versions
SMAP200800011A (it
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Jorg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP200800011(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMAP200800011A publication Critical patent/SMAP200800011A/it
Publication of SMP200800011B publication Critical patent/SMP200800011B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM200800011T 2005-07-20 2006-07-18 Forme cristalline di 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilammino)-benzammide SMP200800011B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
PCT/US2006/027875 WO2007015870A2 (en) 2005-07-20 2006-07-18 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (2)

Publication Number Publication Date
SMAP200800011A SMAP200800011A (it) 2008-02-27
SMP200800011B true SMP200800011B (it) 2008-02-27

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
SM200800011T SMP200800011B (it) 2005-07-20 2006-07-18 Forme cristalline di 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilammino)-benzammide

Country Status (42)

Country Link
US (4) US8343984B2 (enExample)
EP (5) EP2284167B2 (enExample)
JP (3) JP5289948B2 (enExample)
KR (3) KR101651288B1 (enExample)
CN (2) CN103804356A (enExample)
AR (1) AR054846A1 (enExample)
AU (3) AU2006276204A1 (enExample)
BR (1) BRPI0613615B1 (enExample)
CA (1) CA2614334C (enExample)
CR (1) CR9657A (enExample)
CU (1) CU23916B1 (enExample)
CY (2) CY1113076T1 (enExample)
DK (2) DK2284167T4 (enExample)
EA (2) EA016856B1 (enExample)
EC (1) ECSP088119A (enExample)
ES (3) ES2623608T5 (enExample)
GE (1) GEP20115302B (enExample)
GT (1) GT200600315A (enExample)
HN (1) HN2008000311A (enExample)
HR (2) HRP20120573T1 (enExample)
HU (1) HUE031791T2 (enExample)
IL (2) IL188189A0 (enExample)
JO (1) JO3308B1 (enExample)
LT (1) LT2284167T (enExample)
MA (1) MA29626B1 (enExample)
MX (1) MX2008000899A (enExample)
MY (1) MY148554A (enExample)
NI (1) NI200800017A (enExample)
NO (1) NO341930B1 (enExample)
NZ (1) NZ564409A (enExample)
PE (1) PE20070214A1 (enExample)
PH (1) PH12013501590A1 (enExample)
PL (2) PL1912973T3 (enExample)
PT (2) PT1912973E (enExample)
RS (1) RS55929B2 (enExample)
SG (1) SG163620A1 (enExample)
SI (2) SI2284167T2 (enExample)
SM (1) SMP200800011B (enExample)
TN (1) TNSN08029A1 (enExample)
TW (1) TWI406661B (enExample)
UA (1) UA94234C2 (enExample)
WO (1) WO2007015870A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CN101415426A (zh) * 2006-04-07 2009-04-22 诺瓦提斯公司 c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
JP2011507880A (ja) 2007-12-21 2011-03-10 ノバルティス アーゲー 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2530081A3 (en) * 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
BRPI1013366A2 (pt) 2009-03-06 2016-03-29 Novartis Ag uso de derivados de pirimidilaminobenzamida para o tratamento de distúrbios mediados pela quinase contendo zíper de leucina e quinase contendo motivo alfa estéril (zak).
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
RU2012120901A (ru) 2009-10-23 2013-12-10 Новартис Аг Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (en) * 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
EP2571863B1 (en) 2010-06-21 2015-09-23 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (en) * 2010-11-26 2012-05-31 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2014532647A (ja) 2011-10-28 2014-12-08 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
PE20141337A1 (es) 2011-11-14 2014-10-16 Novartis Ag Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
AU2013289175A1 (en) 2012-07-11 2015-01-22 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2906554A4 (en) * 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP2958916B1 (en) * 2013-02-21 2018-09-12 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
BR112015026827A2 (pt) 2013-04-24 2017-09-05 Dr Reddy´S Laboratories Ltd Formas polimórficas de cloridrato de nilotinibe
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
US10016423B2 (en) * 2014-10-16 2018-07-10 Apotex Inc. Solid forms of nilotinib hydrochloride
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
HUE050890T2 (hu) 2016-03-14 2021-01-28 Pliva Hrvatska D O O Nilotinib sók szilárd halmazállapotú formái
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
EP3806858A4 (en) * 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
US12065426B2 (en) 2018-11-05 2024-08-20 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
JP2023513045A (ja) 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
EP4355306A1 (en) 2021-06-19 2024-04-24 Helm AG Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
CN113788817A (zh) * 2021-09-27 2021-12-14 南京海润医药有限公司 一种尼罗替尼半盐酸盐一水合物晶型及其制备方法
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CN1882344A (zh) * 2003-11-18 2006-12-20 诺瓦提斯公司 Kit突变形式的抑制剂
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
US20130165465A1 (en) 2013-06-27
HRP20170634T4 (hr) 2020-02-07
MY148554A (en) 2013-04-30
KR20080027853A (ko) 2008-03-28
BRPI0613615B1 (pt) 2022-02-08
SG163620A1 (en) 2010-08-30
JP5289948B2 (ja) 2013-09-11
PL2284167T5 (pl) 2020-07-27
KR101651288B1 (ko) 2016-08-25
AR054846A1 (es) 2007-07-18
EP2284168A3 (en) 2011-04-13
AU2011202047A1 (en) 2011-05-26
PL2284167T3 (pl) 2017-07-31
CR9657A (es) 2008-04-16
UA94234C2 (uk) 2011-04-26
JP2014221831A (ja) 2014-11-27
DK2284167T4 (da) 2020-03-02
EP2535337B1 (en) 2017-08-23
ECSP088119A (es) 2008-02-20
JP5798101B2 (ja) 2015-10-21
NO341930B1 (no) 2018-02-19
EA016856B1 (ru) 2012-08-30
TNSN08029A1 (en) 2009-07-14
AU2012201453A1 (en) 2012-04-05
HRP20120573T1 (hr) 2012-08-31
DK2284167T3 (en) 2017-05-01
JP2013018789A (ja) 2013-01-31
ES2386974T3 (es) 2012-09-10
CN102358736A (zh) 2012-02-22
EP2543665A3 (en) 2013-05-29
CU23916B1 (es) 2013-07-31
PT1912973E (pt) 2012-09-03
KR20130077915A (ko) 2013-07-09
ES2623608T3 (es) 2017-07-11
WO2007015870A3 (en) 2007-06-07
EP2284167A3 (en) 2011-03-02
NO20080820L (no) 2008-04-15
TWI406661B (zh) 2013-09-01
SMAP200800011A (it) 2008-02-27
ES2648288T3 (es) 2017-12-29
TW200740793A (en) 2007-11-01
WO2007015870A2 (en) 2007-02-08
US8415363B2 (en) 2013-04-09
EA200800201A1 (ru) 2008-06-30
NI200800017A (es) 2009-03-03
RS55929B1 (sr) 2017-09-29
BRPI0613615A2 (pt) 2011-01-18
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
JP2009502795A (ja) 2009-01-29
US20140343087A1 (en) 2014-11-20
HUE031791T2 (en) 2017-08-28
CY1119624T1 (el) 2018-04-04
US20130023548A1 (en) 2013-01-24
JO3308B1 (ar) 2018-09-16
CU20080006A7 (es) 2011-02-24
KR20130085444A (ko) 2013-07-29
DK1912973T3 (da) 2012-07-23
EP2535337A1 (en) 2012-12-19
GEP20115302B (en) 2011-10-10
CA2614334C (en) 2015-04-21
SI2284167T2 (sl) 2020-03-31
EP2284167B2 (en) 2019-11-27
PH12013501590A1 (en) 2015-09-21
EP2543665A2 (en) 2013-01-09
EP2284167B1 (en) 2017-02-01
IL214659A0 (en) 2011-09-27
AU2012201453B2 (en) 2013-09-05
CA2614334A1 (en) 2007-02-08
PE20070214A1 (es) 2007-04-02
CY1113076T1 (el) 2016-04-13
HRP20170634T1 (hr) 2017-06-30
MA29626B1 (fr) 2008-07-01
NZ564409A (en) 2011-07-29
SI2284167T1 (sl) 2017-05-31
PT2284167T (pt) 2017-05-15
EP1912973A2 (en) 2008-04-23
GT200600315A (es) 2007-03-19
EP2284168A2 (en) 2011-02-16
EA013464B1 (ru) 2010-04-30
HK1116783A1 (en) 2009-01-02
US8829015B2 (en) 2014-09-09
ES2623608T5 (es) 2020-06-18
SI1912973T1 (sl) 2012-08-31
LT2284167T (lt) 2017-04-25
EP1912973B1 (en) 2012-06-13
US20080269269A1 (en) 2008-10-30
US8343984B2 (en) 2013-01-01
HN2008000311A (es) 2011-01-24
RS55929B2 (sr) 2020-12-31
AU2006276204A1 (en) 2007-02-08
MX2008000899A (es) 2008-03-18
PL1912973T3 (pl) 2012-09-28
EP2284167A2 (en) 2011-02-16
IL188189A0 (en) 2008-03-20
EA201000145A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
SMP200800011B (it) Forme cristalline di 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilammino)-benzammide
IL187787A0 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP1767508A4 (en) CERAMIC HONEYCOMB STRUCTURE
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
DE602006019282D1 (de) Schwingungsdämpfende zusammensetzung
ATE521238T1 (de) Kristalline modifikationen des pyraclostrobins
EP1930376A4 (en) POLYMERIZABLE COMPOSITION
EP1953125A4 (en) Monolithic refractory
DE602005023936D1 (de) Kühlmittelzusammensetzung
ZA200710799B (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ZA200710457B (en) Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoro-methyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ITFO20050010U1 (it) Mattone isolante per costruzioni edili o mattone probo
ITFO20050007A1 (it) Mattone isolante per costruzioni edili o mattone probo